ClinicalTrials.gg
Not yet recruitingNCT07578272PRIMS-PARKUpdated May 11, 2026

Prevention of Medical, Social, and Psychosocial Risks Following a Parkinson's Disease Diagnosis: A Pilot Study

An interventional study of Patient questionnaires and Caregiver questionnaires in Parkinson Disease, sponsored by University Hospital, Toulouse. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Parkinson Disease by University Hospital, Toulouse — 7 open to participants now, 7 under way, 1 of them phase 3. Parkinson Disease · University Hospital, Toulouse.

Planned enrollment
7th of 25
100 · median 38
Started
2026
with 2 others
No phase
16 of 33
3 open now
Registered
32nd of 33
by date

Among the 33 studies in Parkinson Disease by University Hospital, Toulouse, this one is the 7th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2026, is one of 16 with no phase, and was the 32nd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

7 of the 33 studies in Parkinson Disease by University Hospital, Toulouse are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Parkinson Disease by University Hospital, Toulouse, or all of them as a file.
02

Study summary

Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide, with a prevalence expected to double by 2040. The diagnosis of PD is often a shock for patients and their families, due to a lack of preparation and adequate support. Progress has been made with the establishment of Parkinson's disease expert centers (PDECs) and better-structured care pathways, but limitations remain. The needs of patients, their caregivers, and neurologists at the time of diagnosis were studied, leading to the development of a flexible, adaptable, and multidisciplinary home-based care pathway. This pathway includes multimodal communication tools (booklet and website) and can also be used by caregivers. The aim is to evaluate this pathway at the departmental level and its ability to prevent the medical, social, and psychosocial risks that complicate the care of patients newly diagnosed with PD. Thus, offering the patient, their caregiver and their neurologist a truly flexible and local care pathway built according to their needs, from the moment the disease is announced, could allow for better acceptance of the disease, an improvement in quality of life, the adoption of beneficial practices as well as a patient-caregiver therapeutic alliance with good adherence to drug and non-drug therapies.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • care pathway
  • parkinson
  • caregiver
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For patients:

  • Patients with newly diagnosed Parkinson's disease (\< 1 month)
  • Over 18 years of age

For caregivers (if the caregiver does not wish to participate, the patient can be included):

  • Primary caregiver of a patient with newly diagnosed Parkinson's disease (\< 1 month)
  • Over 18 years of age

Exclusion criteria

Exclusion Criteria:

For patients

  • Institutionalized patients
  • Residents of an area not covered by the intervention zone of specialized neurodegenerative disease teams

For caregivers

- Participants who do not wish to participate

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
Double (Participant, Care provider)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    patients benefiting from a care pathway

    patients benefiting from a flexible and local care pathway

    Other: Patient questionnaires

  • Other
    caregivers of Parkinson's disease patients

    Other: Caregiver questionnaires

Interventions

  • OtherPatient questionnaires

    Patients will need to complete questionnaires to establish and evaluate their care pathway.

  • OtherCaregiver questionnaires

    Caregivers will need to complete questionnaires in order to establish and evaluate the care plan.

06

What researchers measure

Primary outcomes

  1. Evaluate, in newly diagnosed Parkinson's patients, adherence to a new, flexible, and local care pathway after the announcement of the Parkinson's disease.

    Percentage of patients who adhere to the program, i.e., who accept the partial or complete program according to their needs

    Time frame: 6 months after the inclusion

Secondary outcomes

  1. Evaluation of the flexible and local care pathway based on the patient's medical and psychological parameters.

    Responses to the quality of life questionnaire at baseline and 6 months post-inclusion

    Time frame: 6 months after the inclusion

  2. Evaluation of the flexible and local care pathway on the well-being of caregivers

    Caregiver responses to the quality of life questionnaire at baseline and 6 months post-inclusion

    Time frame: 6 months after the inclusion

  3. Evaluation of satisfaction with the flexible and local care pathway

    Responses to the satisfaction questionnaire

    Time frame: 6 months after the inclusion

07

Study locations

1 site
  • Service de Neurologie Cognitive, Comportementale et Mouvement anormaux CHU de Toulouse, Hôpital Pierre Paul Riquet, 31059 Toulouse Cedex 9
    Toulouse, 31300, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 12 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2026
First posted
May 11, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Mar 31, 2028
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07578272
Responsible party
Sponsor
First posted
May 11, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
May 11, 2026

Study contacts

Fabienne ORY MAGNE, MD
Contact
ory.f@chu-toulouse.fr
0561775687 ext. +33

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion